The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis

Himadri Choudhury, Animesh Jindal, Avinash Pathengay, Abhishek Bawdekar, Thomas Albini, Harry W. Flynn

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

The authors evaluate the role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis (TRC) in four patients. Intravitreal injection of trimethoprim/sulfamethoxazole 1.28 mg/0.08 mL with dexamethasone 400 ?g/0.1 mL was injected weekly or biweekly. After the initiation of treatment, a reduction in intraocular inflammation was observed clinically and on optical coherence tomography within 1 week. Three patients regained visual acuity of 20/20, and one patient improved to 20/40 with residual macular scarring. No evidence of retinal toxicity was noted on full-field electroretinogram. Intravitreal trimethoprim/sulfamethoxazole and dexamethasone combination may be an alternative treatment strategy in patients with TRC.

Original languageEnglish (US)
Pages (from-to)137-140
Number of pages4
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume46
Issue number1
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Fingerprint Dive into the research topics of 'The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis'. Together they form a unique fingerprint.

  • Cite this